Literature DB >> 1847257

Isolation of replication-competent molecular clones of visna virus.

K A Staskus1, E F Retzel, E D Lewis, J L Silsby, S St Cyr, J M Rank, S W Wietgrefe, A T Haase, R Cook, D Fast.   

Abstract

Visna virus is the prototypic member of a subfamily of retroviruses responsible for slow infections of animals and humans. As a part of our investigation of the functions of viral gene products in virus replication, we have isolated three infectious molecular clones and determined the complete nucleotide sequences of two of the clones. We have also characterized the progeny of the biologically cloned viral stocks and of the infectious clones and document considerable heterogeneity in plaque size and antigenic phenotype of the former that is reduced to near homogeneity in the progeny of the infectious clones. It thus should now be possible to trace the emergence of antigenic variants of visna virus as well as ascribe defined functions to structural and regulatory genes of the virus in determining neurovirulence and the slow tempo of infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847257     DOI: 10.1016/0042-6822(91)90488-w

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  21 in total

1.  Encapsidation determinants located downstream of the major splice donor in the maedi-visna virus leader region.

Authors:  Helga Bjarnadottir; Bjarki Gudmundsson; Janus Gudnason; Jon J Jonsson
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

2.  Simultaneous mutations in CA and Vif of Maedi-Visna virus cause attenuated replication in macrophages and reduced infectivity in vivo.

Authors:  Bjarki Gudmundsson; Stefán Ragnar Jónsson; Oddur Olafsson; Gudrún Agnarsdóttir; Sigrídur Matthíasdóttir; Gudmundur Georgsson; Sigurbjorg Torsteinsdóttir; Vilhjálmur Svansson; Helga Bryndís Kristbjornsdóttir; Sigrídur Rut Franzdóttir; Olafur S Andrésson; Valgerdur Andrésdóttir
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

3.  Evaluation of two recombinant Maedi-visna virus proteins for use in an enzyme-linked immunosorbent assay for the detection of serum antibodies to ovine lentiviruses.

Authors:  C Power; S Richardson; M Briscoe; J Pasick
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

4.  Monoclonal antibodies to conformational epitopes of the surface glycoprotein of caprine arthritis-encephalitis virus: potential application to competitive-inhibition enzyme-linked immunosorbent assay for detecting antibodies in goat sera.

Authors:  F Ozyörük; W P Cheevers; G A Hullinger; T C McGuire; M Hutton; D P Knowles
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

5.  In vitro activities of purified visna virus integrase.

Authors:  M Katzman; M Sudol
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

6.  Isolation of novel human endogenous retrovirus-like elements with foamy virus-related pol sequence.

Authors:  A Cordonnier; J F Casella; T Heidmann
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

7.  Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  T Dorfman; F Mammano; W A Haseltine; H G Göttlinger
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses.

Authors:  H G Göttlinger; T Dorfman; E A Cohen; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

9.  Oligopeptide-based enzyme immunoassay for ovine lentivirus antibody detection.

Authors:  J Kwang; J V Torres
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948

10.  Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes.

Authors:  J H Simon; T E Southerling; J C Peterson; B E Meyer; M H Malim
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.